Responses
Poster Presentations
Paediatric rheumatology
THU0215 Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.